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A recent Supplement to Clinical Microbiology and Infection entitled
‘Infection control measures to limit the spread of C. difﬁcile’
pointed out that the incidence of C. difﬁcile-associated diarrhoea
(CDAD) has been increasing worldwide, and stressed the impor-
tance of research in the ﬁelds of epidemiology and infection con-
trol [1]. Since 2003, one of the main causes of the increasing
prevalence of CDAD has been claimed to be the emergence of
PCR ribotype 027/NAP1, which has caused epidemics in North
America, the UK, the Netherlands, Belgium and France. The
presence of PCR ribotype 027 in Austria, Japan, Ireland, Ger-
many and Switzerland has also been reported recently [2,3]. The
majority of publications have emphasized that the presence of
this strain is usually associated with more severe symptoms and
signs than those associated with the other more common toxin-
positive strains [4,5]. Whereas PCR ribotype 027 was present in
the population earlier, the majority of the historic strains were
ﬂuoroquinolone sensitive [6]. The overuse of antibiotics such as
ﬂuoroquinolones may lead to the selection and emergence of
resistant strains, and may contribute to the spread of PCR ribo-
type 027, which is usually resistant to erythromycin. Here, the
Eastern European spread of C. difﬁcile PCR ribotype 027 is
reported.
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On 14 June 2007, a 53-year-old male patient with severe
diarrhoea and nausea was admitted to hospital in Budapest,
Hungary. Medical history included hospitalization 2 weeks
before his recent illness because of systemic lupus erythe-
matosus, and previous antibiotic therapy (ceftriaxone, clari-
thromycin and imipenem). Stool specimens were negative for
Salmonella spp., Shigella spp., Yersinia eneterocolitica, Campylo-
bacter spp. and yeasts. In spite of the supportive therapy, the
patient’s condition did not improve, and diarrhoea persisted.
Colonoscopy revealed that the ileal mucosa was intact, but
ulcers were visible in the colon. The patient was therefore
treated with a higher dose of steroid and empiric metronida-
zole. Clostridium difﬁcile toxin detection (using VIDAS Clos-
tridium difﬁcile Toxin A II assay; bioMe´rieux, Craponne,
France) yielded positive scores. Because of the severe and
persistent diarrhoea and the therapeutic failures, antibiotic
therapy was changed to oral vancomycin. On 25 July, high
fever, right-sided pneumonia and respiratory distress devel-
oped; the patient was admitted to the ICU, where he died
shortly thereafter. Escherichia coli sepsis was conﬁrmed by a
positive blood culture. At that time, the patient’s death was
not attributed to C. difﬁcile infection.
Six months later, as part of a national C. difﬁcile survey
in the National Reference Laboratory for Anaerobes in
Hungary, C. difﬁcile was isolated from the faeces of this
patient, which had been kept frozen in the local laboratory.
The isolated strain was positive for toxin A and B genes, and
the presence of binary toxin genes was conﬁrmed.
At the 3¢ end of the tcdA gene, no deletion was detected
using NK9 and NK11 primers as described by Kato et al. [7].
Sequence analysis of the partial tcdC gene of this strain
revealed an 18-bp and single nucleotide deletions, which are
characteristic of the ribotype 027.
Comparison of the results of PCR ribotyping with the pat-
tern of ribotype 027 in the ARL library (Cardiff, UK) and
with the patterns of ribotype 027 control strains (Lume
1 and 10) allowed characterization of this strain as ribotype
027. Using E test, the strain was resistant to erythromycin
(‡256 mg/L) and moxiﬂoxacin (‡32 mg/L), whereas it was
sensitive to metronidazole (1 mg/L) and rifampicin
(£0.002 mg/L), and intermediate resistant to clindamycin
(4 mg/L); the vancomycin MIC was 1 mg/L.
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This case demonstrates the importance of risk factors
such as previous hospitalization, antibiotic therapy, and
immunosuppression in the development of C. difﬁcile-associ-
ated diarrhoea (CDAD), all of which were obvious in this
patient’s medical history.
Although there was no evidence of subsequent severe
cases, or of any outbreak situation in the ward or in the
ICU, this case emphasizes the importance of timely microbial
diagnosis of C. difﬁcile as a causative agent of diseases in hos-
pitalized patients and the importance of the need for increas-
ing awareness of the severity of CDAD and its incidence.
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